J&J’s Erleada Improves Survival for Men with Prostate Cancer

Johnson & Johnson’s (J&J) anti-androgen drug Erleada (apalutamide) provided statistically significant improvements in overall survival for advanced prostate cancer patients, according to the final analysis from a phase 3 trial.

J&J subsidiary Janssen announced that the drug demonstrated a consistent safety profile and statistically significant benefit when added to androgen deprivation therapy (ADT).

The trial’s final analysis confirmed that Erleada plus ADT reduced the risk of death by 35 percent compared to ADT on its own, Janssen said.